Skip to main content
. Author manuscript; available in PMC: 2015 Mar 27.
Published in final edited form as: Am J Transplant. 2008 Oct 6;8(12):2668–2673. doi: 10.1111/j.1600-6143.2008.02430.x

Table 2.

Individual pre- versus posttransplant PSA levels by immunosuppressive regimen

Sirolimus group (n = 19) Tacrolimus group (n = 78)
No change, n (%) 1 (5.3%) 8 (10.3%)
Increase < 1 ng/mL, n (%) 1 (5.3%) 40 (51.3%)
Increase ≥ 1 ng/mL, n (%) 0 (0%) 7 (9.0%)
Decrease < 1 ng/mL, n (%) 8 (42.1%) 19 (24.4%)
Decrease ≥ 1 ng/mL, n (%) 9 (47.4%) 4 (5.1%)
Mean change in PSA [ng/mL] (%) −0.9 (50%)1 +0.2 (11.76%)2

PSA = prostate-specific antigen.

1

p = 0.006 for pre- versus posttransplant PSA.

2

p = 0.24 for pre- versus posttransplant PSA.